Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 30:9:898304.
doi: 10.3389/fsurg.2022.898304. eCollection 2022.

The Relationship Between Systemic Immune Inflammatory Index and Prognosis of Patients With Non-Small Cell Lung Cancer: A Meta-Analysis and Systematic Review

Wei Huang  1 , Jiayu Luo  2 , Jianbo Wen  1 , Mingjun Jiang  1
Affiliations
Review

The Relationship Between Systemic Immune Inflammatory Index and Prognosis of Patients With Non-Small Cell Lung Cancer: A Meta-Analysis and Systematic Review

Wei Huang et al. Front Surg. .

Abstract

Background: The relationship between systemic immune inflammation index (SII) and the prognosis of cancer has always been a subject of intense interest. However, the prognostic value of SII in non-small cell lung cancer (NSCLC) patients remains a controversial topic.

Objective: To evaluate the effect of SII index on prognosis of NSCLC.

Methods: We conducted a comprehensive search of PubMed, EMBASE, and the Cochrane Library databases to determine correlation between SII index, clinicopathological features, overall survival (OS), and progression-free survival (PFS). Odds ratio (ORs) and 95% confidence interval (CIs) were used to assess the connection between SII and clinicopathological parameters, and HRs and 95% CIs were used to assess the connection between SII and survival.

Results: Seventeen studies with 8,877 cases were included in the analysis. Compared with NSCLC patients with low SII level, patients with NSCLC with high SII level had a poor OS (HR = 1.75, 95% CI, 1.50-2.00; P < 0.001) and had a poor PFS (HR = 1.61, 95% CI, 1.25-1.96; P < 0.001). In addition, patients with higher pathological stage (II-III) had higher SII levels (OR = 2.32, 95% CI, 2.06-2.62; P < 0.001).

Conclusions: The SII index is a promising prognostic biomarker for NSCLC and may help clinicians choose appropriate NSCLC treatments.

Keywords: meta-analysis; non-small cell lung cancer; prognosis; systematic review; systemic immune inflammatory index.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Literature screening process.
Figure 2
Figure 2
Forest plot depicting the relationship between SII levels and OS in NSCLC.
Figure 3
Figure 3
Forest plot depicting the relationship between SII levels and PFS in NSCLC.
Figure 4
Figure 4
Forest plot depicting the relationship between SII levels and clinicopathological characteristics of NSCLC patients.
Figure 5
Figure 5
Funnel plot, publication bias assessment.
See this image and copyright information in PMC

References

    1. Amiri A, Pourhanifeh MH, Mirzaei HR, Nahand JS, Moghoofei M, Sahebnasagh R, et al. Exosomes and lung cancer: roles in pathophysiology, diagnosis and therapeutic applications. Curr Med Chem. (2021) 28(2):308–28. 10.2174/0929867327666200204141952 - DOI - PubMed
    1. Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. (2019) 94(8):1623–40. 10.1016/j.mayocp.2019.01.013 - DOI - PubMed
    1. Alexander M, Kim SY, Cheng H. Update 2020: management of non-small cell lung cancer. Lung. (2020) 198(6):897–907. 10.1007/s00408-020-00407-5 - DOI - PMC - PubMed
    1. Osmani L, Askin F, Gabrielson E, Li QK. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. Semin Cancer Biol. (2018) 52(Pt 1):103–9. 10.1016/j.semcancer.2017.11.019 - DOI - PMC - PubMed
    1. Chen Y, Zhou H, Yang S, Su D. Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer. Cell Biochem Funct. (2021) 39(2):277–86. 10.1002/cbf.3577 - DOI - PMC - PubMed

LinkOut - more resources